Condition hub
Living with mctd / overlap
What this illness is, and why nobody wrote a guideline for it.
An overlap, in one person
This mixes parts of systemic sclerosis, myositis and lupus in the same person, and people who have it test positive for an antibody called anti-U1-RNP. Which of the three it borrows most from differs between patients, and that is why no two accounts of it sound alike.
There is no guideline for it
A European reference network searched for care guidelines written for this illness without finding one, so it read the guidelines built for the other three and looked for parts that might apply. That absence is the biggest practical fact about the diagnosis.1
So your plan is borrowed
Your care is built from rules written for lupus, systemic sclerosis or myositis, depending on which symptoms you have. That is a fair way to work when nothing better exists, and it means you are allowed to ask which disease any given rule came from.
The lungs grow quiet problems
Scarring in the lung tissue and high pressure in the lung vessels can both develop a long way before anybody gets short of breath. That is why breathing tests and a heart scan are often part of follow-up even while you feel entirely well.
The four-step plan, applied to mixed connective tissue disease.
Get the right diagnosis
The anti-U1-RNP antibody, an examination for features of all three overlap diseases, and lung tests from the start. Which features you have is what decides whose rules your care gets built from.
Mixed connective tissue disease and labs →Clean up your food
No diet trial has been run in this illness, so any food advice you are given was written for one of the other three. Eating well still does everything it does for anybody else.
Mixed connective tissue disease and diet →Detox your daily life
Silica and solvents have been studied in the diseases this one overlaps and never measured in this one. Mention your work history anyway, because your lungs are reason enough to raise it.
Mixed connective tissue disease and environment →Build a stronger body
No exercise trial exists here either, so what you get is borrowed from lupus and from systemic sclerosis. Build from what you can do now, and tell whoever writes your program which features you have.
Mixed connective tissue disease and exercise →
Pro tip
Ask which disease each rule in your plan came from. In an illness with no guideline of its own the answer tells you how sure to be about it, and two careful rheumatologists can reasonably plan your care in different ways, so a second opinion that disagrees is not proof that either of them is wrong.
Why there is so little to read
What that means for your care
This doesn't mean your care is a guess. Rheumatologists handle overlap illnesses all the time, and the symptoms answer treatment much as they do in the diseases the rules came from. What it does mean is that the truth here is less settled than the confident tone of some advice suggests.
Two careful doctors can plan your care in different ways, more here than in a disease with an agreed protocol, so a second opinion that disagrees isn't proof that one of them is wrong. You're also allowed to ask which disease a rule came from, and the answer tells you how sure to be about it. That question is fair in any illness and it is a necessary one here.
What gets watched, and why
Which symptoms you have decides what gets checked, so the answer is yours instead of general. The lungs are the clearest case, because two lung problems can grow a long way before anyone gets short of breath. One is scarring in the lung tissue, which doctors call interstitial lung disease, and the other is high pressure in the vessels feeding the lungs.
That's why breathing tests and a heart scan called an echocardiogram are often part of follow-up, while kidney tests, muscle blood tests and blood counts get checked when those symptoms are present. Ask your rheumatologist which schedule applies to you, and ask what each test is looking for. In an illness with no protocol, knowing your own plan counts for more than usual.
Common misconceptions.
Myth. It's the same as lupus, so the treatment is the same.
Reality. Hydroxychloroquine is shared. But MCTD has a higher PAH risk than lupus, lower nephritis risk, and often features that look more like scleroderma, esophageal dysmotility, sclerodactyly. Treatment is tailored to the dominant feature, not generic lupus management.
In plain words. MCTD and lupus share one drug, and they part company after that. MCTD brings more lung-pressure risk and less kidney risk, and some of it behaves like scleroderma. Treatment follows your own main problem.
Myth. If I feel okay, I don't need annual screening.
Reality. PAH in MCTD often progresses silently. By the time symptoms appear, significant pulmonary vascular disease has occurred. Annual echocardiogram catches early elevations in pulmonary pressure when treatment is most effective. This isn't optional.
In plain words. High lung pressure builds here without warning signs. By the time you feel it, damage is done. A yearly heart scan catches it early, when treatment works best. Don't skip it.
When to see a rheumatologist.
See a rheumatologist if you have:
- Raynaud's phenomenon plus swollen hands ('puffy fingers')
- Joint pain plus a positive ANA at high titer
- Overlapping features of lupus, scleroderma, or myositis
- Confirmed anti-U1-RNP antibody on a previous test
- Unexplained shortness of breath plus Raynaud's
- Esophageal symptoms plus Raynaud's
The problems worth catching early here grow without symptoms at first, above all in the lungs, so waiting until you feel unwell is not a plan. Ask which monitoring schedule applies to you and what each test is looking for, because you may be the only person who sees all of your care.
References.
- Chaigne B; Scirè C; Talarico R et al. Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open. 2018;4:e000783. 10.1136/rmdopen-2018-000783Systematic literature review for clinical practice guidelines
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.